1、 谢育坤, 宁婷, 徐鹏,等. MTHFR C677T基因多态性、血浆HCY水平与精神分裂症患者心血管风险的相关性[J]. 广州医药,2020,51(1):109-112,116. 谢育坤, 宁婷, 徐鹏,等. MTHFR C677T基因多态性、血浆HCY水平与精神分裂症患者心血管风险的相关性[J]. 广州医药,2020,51(1):109-112,116.
2、 HAN S, XU Y, GAO M, et al. Serum apolipoprotein E concentration and polymorphism influence serum lipid levels in Chinese Shandong Han population[J]. Medicine (Baltimore), 2016,95(50):e5639. HAN S, XU Y, GAO M, et al. Serum apolipoprotein E concentration and polymorphism influence serum lipid levels in Chinese Shandong Han population[J]. Medicine (Baltimore), 2016,95(50):e5639.
3、 孟强, 张雪海, 张新卫. 中国人群载脂蛋白E基因多态性与高脂血症关系的Meta分析[J]. 中国预防医学杂志,2015(4):304-307. 孟强, 张雪海, 张新卫. 中国人群载脂蛋白E基因多态性与高脂血症关系的Meta分析[J]. 中国预防医学杂志,2015(4):304-307.
4、 D'AGOSTINO R B, VASAN R S, PENCINA M J, et al. General cardiovascular risk profile for use in primary care: the framingham heart study[J]. Circulation, 2008(117):743-753. D'AGOSTINO R B, VASAN R S, PENCINA M J, et al. General cardiovascular risk profile for use in primary care: the framingham heart study[J]. Circulation, 2008(117):743-753.
5、 GUPTA A K, RANI K, SWARNKAR S, et al. Evaluation of serum Apolipoprotein E as a potential biomarker for pharmacological therapeutic efficacy monitoring in dopamine dictated disease spectrum of schizophrenia and parkinson's disease: a preliminary study[J]. J Cent Nerv Syst Dis, 2018(10):1-8. GUPTA A K, RANI K, SWARNKAR S, et al. Evaluation of serum Apolipoprotein E as a potential biomarker for pharmacological therapeutic efficacy monitoring in dopamine dictated disease spectrum of schizophrenia and parkinson's disease: a preliminary study[J]. J Cent Nerv Syst Dis, 2018(10):1-8.
6、 MARAIS A D. Apolipoprotein E in lipoprotein metabolism, health and cardiovascular disease[J]. Pathol, 2019,51(2):165-176. MARAIS A D. Apolipoprotein E in lipoprotein metabolism, health and cardiovascular disease[J]. Pathol, 2019,51(2):165-176.
7、 赵帅, 周晓琴. 精神分裂症患者心血管疾病风险因素的研究进展[J]. 安徽医药,2018,22(4):591-594. 赵帅, 周晓琴. 精神分裂症患者心血管疾病风险因素的研究进展[J]. 安徽医药,2018,22(4):591-594.